HC Wainwright & Co. Reiterates Buy on Zevra Therapeutics, Maintains $20 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Oren Livnat has reiterated a Buy rating for Zevra Therapeutics (NASDAQ:ZVRA) and maintained a $20 price target.
September 30, 2024 | 10:28 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated a Buy rating for Zevra Therapeutics, maintaining a $20 price target, indicating confidence in the company's potential.
The reiteration of a Buy rating and maintenance of a $20 price target by a reputable analyst suggests positive sentiment and potential upside for Zevra Therapeutics. This could lead to increased investor interest and a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100